F-star Appoints Nessan Bermingham as Chairman of its Board of Directors

CAMBRIDGE, England--(BUSINESS WIRE)-- f-Star, a biopharmaceutical company developing novel bispecific antibodies, today announces the appointment of Nessan Bermingham, Ph.D. as Chairman of its Board of Directors. Nessan succeeds John Edwards who has been F-star’s Chairman for seven years and will remain as a non-executive director.

Dr Nessan Bermingham is a highly qualified healthcare entrepreneur, with an impressive track record of building, growing and consolidating both private and public biotech companies. Based in Boston, USA, he has over a decade of experience in the life science industry, venture capital, secondary and public markets. Most recently, Nessan co-founded Intellia Therapeutics, a company developing potentially curative genome editing treatments for people living with severe and life-threatening diseases, and led it to a successful listing on NASDAQ (NASDAQ:NTLA).

John Haurum, CEO of F-star said On behalf of the Board, I would like to thank John Edwards for his remarkable seven-year tenure as our Chairman and we look forward to his continuing contribution to F-star’s success. Nessan Bermingham brings a huge amount of experience, complementing the skills and expertise that we already have and I am confident he will play a vital role in supporting the next stage of our corporate development, helping us achieving our ambition to become a key player in the immuno-oncology space.”

Commenting on his appointment Nessan Bermingham, Chairman of F-star said “It is an exciting time to be joining F-star’s Board. The Company is widely recognised as a leader in the bispecific antibody space and I am thrilled by the opportunities and prospects ahead of us. I am looking forward to supporting F-star in its mission to develop first-in-class therapies that have the potential to become life-changing treatments for cancer patients.”

- ENDS –

About F-star

F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients. Through our highly efficient Modular Antibody Technology™ platform, we are building and progressing an extensive immuno-oncology pipeline of mAb²™, a novel class of disruptive bispecific antibodies designed to unlock new biology which cannot be achieved by combining monospecific drugs. F-star’s technological expertise and scientific approach have been validated through strategic partnerships with leaders in the pharma and biotech industries.

Find out more at www.f-star.com. Connect with us via LinkedIn and Twitter.



Pierre Peotta
Communications Manager
+44 (0)1223 948 094
+44 (0)7392 080 279
Instinctif Partners (UK and RoW)
Sue Charles/Ashley Tapp
+44 (0)20 7866 7923
Lazar Partners (USA)
Glenn Silver
+1 212 867 1762


Source: F-star

Back to news